Authors : A. Lahari; K. Gnanankitha; V. Poojitha; Paila. Bhanuji Rao; Nimmala. Phani Satyavathi

Volume/Issue : Volume 10 - 2025, Issue 2 - February

Google Scholar : https://tinyurl.com/56cbunuf

Scribd : https://tinyurl.com/3u927e9h

DOI : https://doi.org/10.5281/zenodo.14959364

Abstract : This journal explores the role of environmental influences in increasing the risk of developing schizophrenia, a complex mental health condition. While genetics play a significant role, research suggests that environmental elements such as prenatal infections, early life trauma, growing up in urban areas, and substance abuse significantly elevate the chances of schizophrenia, particularly in individuals with a genetic vulnerability. The interaction between these environmental triggers and genetic factors is complex, and gaining a deeper understanding of this relationship is essential for creating better prevention and treatment strategies. This review emphasizes the importance of considering both genetic and environmental factors for more effective management and prevention of the disorder.

Keywords : Environmental Factors, Risk Factors, Mechanisms and Pathways, Public Health and Prevention.

References :

1. Lewis DA, Lieberman JA. 2000. Catching upon schizophrenia: natural history and neurobiology. Neuron 28:325–34
2. Lewis DA, Pierri JN, Volk DW, Melchitzky DS,Woo T-U. 1999. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol. Psychiatry 46:616–26
3. Lillien L. 1995. Changes in retinal cell fate induced by overexpression of EGF receptor.Nature 377:158–62
4. Lipska BK, Weinberger DR. 2000. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23:223–39
5. Malmberg A, Lewis G, David A, Allebeck P.1998. Premorbid adjustment and personality in people with schizophrenia. Br. J. Psychiatry 172:308–13 INTRODUCTION
6. Bowen, F. P., Kamienny, R. E., Burns, M. M. & Yahr, M. D. (1975).Parkinsonism: effects of levodopa treatment on concept formation Neurology 25, 701-704.
7. Brindley, G. & Merton, P A. (1960). The absence of position sense in the human eye. Journal of Physiology London, 153, 127-130.
8. Brown, R., Colter, N., Corsellis, J. A. N., Crow, T. J., Frith, C. D.,Jagoe, R., Johnstone, E. C. & Marsh, L. (1986). Post-mortem evidence for structural brain changes in schizophrenia. Archives of General Psychiatry (in the press).
9. Callaway, E. & Naghdi, S. (1981). An information processing model of schizophrenia. Archives of General Psychiatry 39, 339-347.
10. Carpenter, M. D. (1976). Sensitivity to syntactic structure: good versus poor premorbid schizophrenics. Journal of Abnormal Psychology 85, 41-50.
11. Cohen, B. D. (1978). Referent communication disturbances in schizophrenia. Language and Cognition in Schizophrenia, (ed.S. Schwartz), pp. 1-34. Erlbaum: Hillsdale, NJ.
12. Connell, P. H. (1958). Amphetamine Psychosis. Institute of Psychiatry Maudsley Monographs No. 5. Chapman and Hall: London.
13. Cromwell, R. J. (1968). Stimulus redundancy and schizophrenia Journal of Nervous and Mental Disease 146, 360-375.
14. Crow, T. J. (1980a). Molecular pathology of schizophrenia. More than one dimension of  Pathology? British Medical Journal 280 66-68.
15. Crow, T. J. (19806). Drug treatment of schizophrenia and itsrelationship to disturbances of dopaminergic transmission. In TheBiochemistry of Psychiatric Disturbances (ed. G. Curzon), pp.73-88. Wiley: Chichester.
16. Dennett, D. C. (1969). Content and Consciousness. Routledge andRegan Paul: London.Denny-Brown D. (1968). Clinical symptomatology of diseases of thebasal ganglia. In Handbook of Clinical Neurology. Volume 6, (ed.P. J. Vinken and G. W. Bruyn), p. 136. North Holland:Amsterdam.
17. Dickinson, A. (1980). Contemporary Animal Learning Theory.Cambridge University Press: Cambridge.Done, D. J. & Frith, C. D. (1984a. The effect of context during word perception in schizophrenic patients. Brain and Language 23318-336.
18. D. J. & Frith, C. D. (1984*). Automatic and strategic controlof eye movements in schizophrenia. In Theoretical and AppliedAspects of Eye Movement Research, (ed. A. G. Gale andF. Johnson), pp. 481-487.
19. Elsevier: Amsterdam.Feighner, J. P., Robins, E. Guze, S. B., Woodruff, R, WinokurG. & Munoz, R. (1972)Diagnostic criteria for us in psychiatric research. Archives of General Psychiatry 26, 57-63.
20. Feinberg, I. (1978). Efference copy and corollary discharge: implications for thinking and its disorders. Schizophrenia Bulletin4, 636-640.
21. Flowers, K. (1978). Lack of prediction in the motor behaviour of Parkinsonism. Brain 101, 35-52.
22. Flowers, K. A. (1982). Frontal lobe signs as a component ofParkinsonism. Behaviour and Brain Research 5, 100-101.
23. Frith, C. D. (1979). Consciousness, information processing and schizophrenia. British Journal of Psychiatry 134, 225-235.
24. Frith, C. D. & Done, D. J. (1983). Stereotyped responding by schizophrenic patients in a two-choice guessing task. Psychological Medicine 13, 779-786.
25. Frith, C. D. & Done, D. J. (1987). Routes to action in reaction time tasks. Psychological Research (in  the press).
26. Gerver, D. (1967). Linguistic rules and the perception and recall of speech by schizophrenic patients. Journal of Social and Clinical Psychology 6, 204-211.
27. Goldberg, G. (1985). Supplementary motor area structure and function: review and hypotheses. Behavioral and Brain Sciences 8, 567-616.
28. Goldberg, G., Mayer, N. H. & Toglia, J. U. (1981). Medial frontal cortical infarction and the alien hand sign. Archives of Neurology 38, 683-686.
29. Green, P. & Preston, M. (1981). Reinforcement of vocal correlates of auditory hallucinations by auditory feedback. British Journal of Psychiatry 139, 204-208.
30. Aleman A, Kahn RS, Selten JP (2003). Sex differences in the risk of  schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry. 60: 565–571.
31. Andreou D, Söderman E, Axelsson T, Sedvall GC, Terenius L, Agartz I, et al. (2014). Polymorphisms in genes implicated in dopamine, serotonin and noradrenalin metabolism suggest association with cerebrospinal fluid monoamine metabolite concentrations in psychosis. Behav Brain Funct. 10: 26.
32. Arroll MA, Wilder L, Neil J (2014). Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutr J. 13: 91.
33. Avramopoulos D, Pearce BD, McGrath J, Wolyniec P, Wang R, Eckart N, et al. (2015). Infection and inflammation in schizophrenia and bipolar disorder: a genome wide study for interactions with genetic variation. PLoS One. 10: e0116696.
34. Boydell J (2001). Risk factors for schizophrenia. Expert Rev Neurother. 1: 183–191.
35. Butterworth RF (1998). Excitatory neurons and schizophrenia. Lancet. 352: 1643.
36. Cannon M, Jones PB, Murray RM (2002). Obstetric complications and schizophrenia and meta-analytic review. Am J Psychiatry.159: 1080–1092.
37. Clarke MC, Harley M, Cannon M (2006a).EPEDIMOLOGY
38. Schwartz PJ (2011). Season of birth in schizophrenia: a maternal-fetal chronobiological hypothesis. Med Hypotheses. 76: 785–793.
39. Semple DM, McIntosh AM, Lawrie SM (2005). Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 19: 187–194.
40. Sørensen HJ, Mortensen EL, Reinisch JM, Mednick SA (2005). Breastfeeding and risk of schizophrenia in the Copenhagen Perinatal Cohort. Acta Psychiatr Scand. 112: 26–29.
41. Šerý O, Přikryl R, Častulík L, Št’astný F (2010). A118G polymorphism of OPRM1 gene is associated with schizophrenia. J Mol Neurosci. 41: 219–222.
42. Šerý O, Šťastný F, Zvolský P, Hlinomazová Z, Balcar VJ (2011). Association between Val66Met polymorphism of Brain-Derived Neurotrophic Factor (BDNF) gene and a deficiency of colour vision in alcohol-dependent male patients. Neurosci Lett. 499: 154–157.
43. Šerý O, Povová J, Balcar VJ (2014). Perspectives in genetic prediction of Alzheimer’s disease. Neuro Endocrinol Lett. 35: 359–366.
44. Šerý O, Sultana N, Kashem MA, Pow DV, Balcar VJ (2015a). GLAST But Not Least-Distribution, Function, Genetics and Epigenetics of L-Glutamate Transport in Brain-Focus on GLAST/EAAT1. Neurochem Res. DOI 10.1007/s11064-015-1605-2
45. Šerý O, Lochman J, Povová J, Janout V, Plesník J, Balcar VJ (2015b). Association between 5q23.2-located polymorphism of CTXN3 gene (Cortexin 3) and schizophrenia in European-Caucasian males; implications for the aetiology of schizophrenia. Behav Brain Funct. 11: 10.
46. Szkultecka-Dębek M, Walczak J, Augustyńska J, Miernik K, Stelmachowski J, Pieniążek I, et al. (2015). Epidemiology and Treatment Guidelines of Negative Symptoms in Schizo-phrenia in Central and Eastern Europe: A Literature Review. Clin Pract Epidemiol Ment Health. 11: 158–16552 Szöke A, Charpeaud T, Galliot AM, Vilain J, Richard JR, Leboyer M, et al. (2014). Rural-urban variation in incidence of psychosis in France: a prospective epidemiologic study in two contrasted catchment areas. BMC Psychiatry. 14: 78
47. Takei N, Murray RM, Sham P, O’Callaghan E (1995). Schizophrenia risk for women from in utero exposure to influenza. Am J Psychiatry. 152: 150–151.54 Tandom R, Keshavan MS, Nasrallah HA (2008). Schizophrenia, “Just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 102: 1–18.
48. Thoma P, Daum I (2013). Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. Psychiatry Clin Neurosci. 67: 367–383.
49. ÚZIS ČR (2014).RISK FACTORS
50. Addington J, Epstein I, Liu L et al (2011) A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 125:54–61
51. Amminger GP, Schafer MR, Papageorgiou K et al (2010) Long chain omega-3 fatty acids for indicated prevention of psychoticdisorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67:146–154
52. Antonini L, Mollica C, Auriti A et al (2014) A prognostic index for risk stratification for acute heart failure and death in subjects with ischemic cardiomyopathy and cardiac defibrillator. Heart Vessels. doi:10.1007/s00380-014-0494-7
53. Barch DM, Bustillo J, Gaebel W et al (2013) Logic and justification for dimensional assessment of symptoms and relatedclinical phenomena in psychosis: relevance to DSM-5. Schizophr Res 150:15–20
54. Bechdolf A, Muller H, Stutzer H et al (2011) Rationale and baseline characteristics of prevent: a second-generation intervention trial in subjects at-risk (prodromal) of developing firstepisode  psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. Schizophr Bull 37(Suppl 2):S111–S121
55. Bechdolf A, Wagner M, Ruhrmann S et al (2012) Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry 200:22–29
56. Bell RQ (1992) Multiple-risk cohorts and segmenting risk assolutions to the problem of false positives in risk for the major psychoses. Psychiatry 55:370–381
57. Bodatsch M, Ruhrmann S, Mu¨ller R, Klosterko¨tter J, Brockhaus-Dumke A (2010) Mismatch negativity is reduced inschizophrenia patients with deficit syndrome. Schizophr Res117:360–361
58. Bodatsch M, Ruhrmann S, Wagner M et al (2011) Prediction of psychosis by mismatch negativity. Biol Psychiatry 69:959–966
59. Fusar-Poli P, Borgwardt S, Bechdolf A et al (2013) The psychosis high-risk state: a comprehensive state-of-the-art review.JAMA Psychiatry 70:107–120
60. Hutton P, Taylor PJ (2014) Cognitive behavioural therapy forpsychosis prevention: a systematic review and meta-analysis.Psychol Med 44:449–468
61. Lee TY, Shin YS, Shin NY et al (2014) Neurocognitive function as a possible marker for remission from clinical high risk for psychosis. Schizophr Res 153:48–53
62. Lip GY, Edwards SJ (2006) Stroke prevention with aspirin,warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res118:321–333
63. Marshall M, Lockwood A (2004) Early intervention for psychosis. Cochrane Database Syst Rev 4:CD004718
64. McGlashan T, Walsh B, Woods SW (2010) The psychosis-risk syndrome. Handbook for diagnosis and follow-up. Oxford University Press, New York
65. McGlashan TH, Zipursky RB, Perkins D et al (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163:790–799
66. McGorry PD, Nelson B, Phillips LJ et al (2013) Randomizedcontrolled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. Journal clin psychiatry 74:349–356
67. McGorry PD, Yung AR, Phillips LJ (2003) The ‘‘close-in’’ or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder.Schizophr Bull 29:771–790
68. McGorry PD, Yung AR, Phillips LJ et al (2002) Randomizedcontrolled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59:921–928
69. Michel C, Ruhrmann S, Schimmelmann BG, Klosterko¨tter J,Schultze-Lutter F (2014) A stratified model for psychosis prediction in clinical practice. Schizophr Bull. doi:10.1016/j.schres.2014.01.025
70. Michel C, Schimmelmann BG, Kupferschmid S, Siegwart M,Schultze-Lutter F (2014) Reliability of telephone assessments of at-risk criteria of psychosis: a comparison to face-to-face interviews. Schizophr Res 153:251–253
71. Miklowitz DJ, O’Brien MP, Schlosser DA et al (2014) Family focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry 53:848–858
72. Morrison AP, French P, Stewart SL et al (2012) Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 344:e2233
73. Morrison AP, French P, Walford L et al (2004) Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 185:291–297
74. Mo¨ssner R, Schuhmacher A, Wagner M et al (2010) Daoa/g72 predicts the progression of prodromal syndromes to first episode psychosis. Eur Arch Psychiatry Clin Neurosci 260:209–215
75. Mrazek PJ, Haggerty HJ (1994) Reducing risks for mental disorders: frontiers for preventive research. Academy Press, Washington
76. Nelson B, Yuen HP, Wood SJ et al (2013) Long-term follow-up of a group at ultra high risk (‘‘prodromal’’) for psychosis: the pace 400 study. JAMA Psychiatry 70:793–802
77. Nieman DH, Ruhrmann S, Dragt S et al (2013) Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables. Schizophr Bull.doi:10.1093/schbul/sbt145
78. Nieman DH, Velthorst E, Becker HE et al (2013) The strauss and carpenter prognostic scale in subjects clinically at high risk of psychosis. Acta Psychiatr Scand 127:53–61
79. Nuechterlein KH, Dawson ME, Gitlin M et al (1992) Developmental processes in schizophrenic disorders: longitudinal studies of vulnerability and stress. Schizophr Bull 18:387–42561. Olvet DM, Carrion RE, Auther AM, Cornblatt BA (2013) Self awareness of functional impairment in individuals at clinical high-risk for psychosis. Early Interv Psychiatry. doi:10.1111/eip.12086
80. Perez VB, Woods SW, Roach BJ et al (2014) Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. Biol Psychiatr 75:459–469
81. Perkins DO, Jeffries CD, Addington J et al (2014) Towards a psychosis risk blood diagnostic for persons experiencing high risk symptoms: preliminary results from the napls project. Schizophr Bull. doi:10.1093/schbul/sbu099
82. Piskulic D, Addington J, Cadenhead KS et al (2012) Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res 196:220–224
83. Preti A, Cella M (2010) Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res 123:30–36
84. Pukrop R, Ruhrmann S (2012) Neurocognitive indicators ofhigh-risk states for psychosis. In: Borgwardt S, McGuire P, Fusar Poli P (eds) Vulnerability to psychosis: from neuroscience to psychopathology. Psychology Press, Hove, pp 73–94
85. Riecher-Ro¨ssler A, Aston J, Ventura J et al (2008) the basel screening instrument for psychosis (BSIP): development,structure, reliability and validity. Fortschr Neurol Psychiatr76:207–216
86. Riecher-Ro¨ssler A, Pflueger MO, Aston J et al (2009) Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. Biol Psychiatry 66:1023–1030
87. Ro¨ssler W, Salize HJ, van Os J, Riecher-Ro¨ssler A (2005) Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 15:399–409
88. Ruhrmann S, Klosterko¨tter J, Bodatsch M et al (2012) Pharmacological prevention and treatment in clinical at-risk statesfor psychosis. Curr Pharm Des 18:550–557
89. Ruhrmann S, Klosterko¨tter J, Bodatsch M et al (2012) Chances and risks of predicting psychosis. Eur Arch Psychiatry ClinNeurosci 262(Suppl 2):S85–S90
90. Ruhrmann S, Schultze-Lutter F, Klosterk¨tter J (2003) Early detection and intervention in the initial prodromal phase ofschizophrenia. Pharmacopsychiatry 36(Suppl 3):S162–S167
91. Ruhrmann S, Schultze-Lutter F, Klosterko¨tter J (2010) Probably at-risk, but certainly ill—advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res 120:23–37
92. Ruhrmann S, Schultze-Lutter F, Klosterko¨tter J (2010) Sub threshold states of psychosis—a challenge to diagnosis and treatment. Clin Neuropsychiatry 7:72–87
93. Ruhrmann S, Schultze-Lutter F, Salokangas RK et al (2010) Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 67:241–251
94. Salokangas RK, Heinimaa M, From T et al (2014) Short-term functional outcome and premorbid adjustment in clinical high risk patients. Results of the epos project. Eur Psychiatry 29:371–380
95. Salokangas RK, Nieman DH, Heinimaa M et al (2013) Psychosocial outcome in patients at clinical high risk of psychosis: a prospective follow-up. Soc Psychiatry Psychiatr Epidemiol48:303–311
96. Salokangas RKR, Ruhrmann S, von Reventlow HG et al (2012) Axis i diagnoses and transition to psychosis in clinical high-risk patients epos project: prospective follow-up of 245 clinical high risk outpatients in four countries. Schizophr Res 138:192–197
97. Schaffner N, Schimmelmann BG, Niedersteberg A, Schultze Lutter F (2012) pathways-to-care for first-episode psychotic patients–an overview of international studies. Fortschr Neurol Psychiatr 80:72–78
98. Schimmelmann BG, Walger P, Schultze-Lutter F (2013) The significance of at-risk symptoms for psychosis in children and adolescents. Can J psychiatry Revue canadienne de psychiatrie 58:32–40
99. Schmidt SJ, Grunert VM, Schimmelmann BG, Schultze-Lutter F,Michel C (2014) Differences in coping, self-efficacy, and external control beliefs between patients at-risk for psychosis and patients with first-episode psychosis. Psychiatry Res 219:95–102
100. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG et al (2015) EPA guidance on the early intervention in clinical high-risk states of psychoses. European Psychiatry (in press)
101. Schultze-Lutter F (2009) Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull 35:5–8
102. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterko¨tter J (2007) Schizophrenia proneness instrument - adult version (spia). Giovanni Fioriti, Rome
103. Schultze-Lutter F, Klosterko¨tter J, Picker H, Steinmeyer E, Ruhrmann S (2007) Predicting first-episode psychosis by basicsymptom criteria. Clin Neuropsychiatry 4:11–22

104. Schultze-Lutter F, Klosterko¨tter J, Ruhrmann S (2014) Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms. Schizophr Res 154:100–106
105. Schultze-Lutter F, Michel C, Schmidt SJ et al (2015) EPA guidance on the early detection of clinical high risk states of psychoses. European Psychiatry (in press)
106. Schultze-Lutter F, Ruhrmann S, Berning J, Maier W,Klosterko¨tter J (2010) Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state.Schizophr Bull 36:182–191
107. Schultze-Lutter F, Schimmelmann BG, Ruhrmann S, Michel C (2013) ‘A rose is a rose is a rose’, but at-risk criteria differ. Psychopathology 46:75–87
108. Smieskova R, Fusar-Poli P, Allen P et al (2010) Neuroimaging predictors of transition to psychosis-a systematic review and meta-analysis. Neurosci Biobehav Rev 34:1207–1222
109. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, KendallT (2013) Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 346:f185
110. Tarbox SI, Addington J, Cadenhead KS et al (2013) Premorbid functional development and conversion to psychosis in clinical high-risk youths. Dev Psychopathol 25:1171–1186
111. Valmaggia LR, Stahl D, Yung AR et al (2013) Negative psychotic symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: a latent class cluster analysis study. Psychol Med 43:2311–2325
112. van der Gaag M, Nieman DH, Rietdijk J et al (2012) Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull 38:1180–1188
113. van der Gaag M, Smit F, Bechdolf A et al (2013) Preventing a controlled prevention trails of 12 month and longer term follow- ups schizophr res 149: 56-62.
114. Hosak L (2013). New findings in the genetics of schizophrenia World J Psychiatry. 3: 57–61.
115. Hosáková J, Jarosova D (2015). Quality of life and needs of hospitalized schizophrenic patients in the Czech Republic. Neuro Endocrinol Lett. 36: 288–293.